VDM 11 - CAS 313998-81-1
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
Cannabinoid Receptor
VDM 11 is a potent and selective inhibitor of the anandamide membrane transporter (AMT) (IC50 = 4-11 μM), blocking cellular reuptake of anandamide and leads to inactivation of the endocannabinoid signal. VDM 11 also displays negligible agonist activity at the hVR1 receptor and weak action at CB1 and CB2 receptors.
Brife Description:
AMT inhibitor
≥98% by HPLC
VDM 11; VDM11; VDM-11; (5Z,8Z,11Z,14Z)-N-(4-Hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide; N-(4-Hydroxy-2-methylphenyl)arachidonylamide
Canonical SMILES:
1.Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens.
Sperlágh B1, Windisch K, Andó RD, Sylvester Vizi E. Neurochem Int. 2009 Jun;54(7):452-7. doi: 10.1016/j.neuint.2009.01.017. Epub 2009 Feb 6.
We examined the effect of cannabinoid receptor activation on basal and electrical field simulation-evoked (25 V, 2 Hz, 240 shocks) [(3)H]dopamine efflux in the isolated rat nucleus accumbens in a preparation, in which any effect on the dendrites or somata of ventral tegmental projection neurons was excluded. The cannabinoid agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate (WIN55,212-2, 100 nM) significantly enhanced stimulation-evoked [(3)H]dopamine release in the presence of the selective dopamine transporter inhibitor 1-[2-[bis-(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride (GBR12909, 100 nM). GBR12909 (100 nM-1 microM), when added alone, increased the evoked [(3)H]dopamine efflux in a concentration-dependent manner. The stimulatory effect of WIN55,212-2 on the evoked tritium efflux was inhibited by the selective CB1 cannabinoid receptor antagonist N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251, 100 nM) and by the GABA(A) receptor antagonist bicuculline (10 microM).
2.Anandamide transport inhibitor AM404 and structurally related compounds inhibit synaptic transmission between rat hippocampal neurons in culture independent of cannabinoid CB1 receptors.
Kelley BG1, Thayer SA. Eur J Pharmacol. 2004 Aug 2;496(1-3):33-9.
N-(hydroxyphenyl)-arachidonamide (AM404) is an inhibitor of endocannabinoid transport. We examined the effects of AM404 on glutamatergic synaptic transmission using network-driven increases in intracellular Ca2+ concentration ([Ca2+] spikes) as an assay. At a concentration of 1 microM AM404 inhibited [Ca2+]i spiking by 73+/-8%. The cannabinoid CB1 receptor antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride (SR141716A), the vanilloid VR1 receptor antagonist capsazepine (CPZ), and treatment with pertussis toxin failed to block AM404-mediated inhibition. AM404 (3 microM) inhibited action-potential-evoked Ca2+ influx by 58+/-3% but failed to affect calcium influx evoked by depolarization with 30 mM K+, suggesting that the inhibition of electrically evoked [Ca2+]i increases and that [Ca2+]i spiking was due to inhibition of Na+ channels. Palmitoylethanolamide (PMEA), capsaicin (CAP) and (5Z,8Z,11Z,14Z)-N-(4-hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide (VDM11), compounds structurally similar to AM404, inhibited [Ca2+]i spiking by 34+/-10%, 42+/-18% and 67+/-12%, respectively.
3.Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations.
De Lago E1, Gustafsson SB, Fernández-Ruiz J, Nilsson J, Jacobsson SO, Fowler CJ. J Neurochem. 2006 Oct;99(2):677-88. Epub 2006 Aug 8.
Compounds blocking the uptake of the endogenous cannabinoid anandamide (AEA) have been used to explore the functions of the endogenous cannabinoid system in the CNS both in vivo and in vitro. In this study, the effects of four commonly used acyl-based uptake inhibitors [N-(4-hydroxyphenyl)arachidonylamide (AM404), N-(4-hydroxy-2-methylphenyl) arachidonoyl amide (VDM11), (5Z,8Z,11Z,14Z)-N-(3-furanylmethyl)-5,8,11,14-eicosatetraenamide (UCM707) and (9Z)-N-[1-((R)-4-hydroxybenzyl)-2-hydroxyethyl]-9-octadecen-amide (OMDM2)] and the related compound arvanil on C6 glioma cell viability were investigated. All five compounds reduced the ability of the cells to accumulate calcein, reduced the total nucleic acid content and increased the activity of lactate dehydrogenase recovered in the cell medium. AM404 (10 microm) and VDM11 (10 microm) acted rapidly, reducing cell viability after 3 h of exposure when cell densities of 5,000 per well were used.
4.Endocannabinoids mediate muscarine-induced synaptic depression at the vertebrate neuromuscular junction.
Newman Z1, Malik P, Wu TY, Ochoa C, Watsa N, Lindgren C. Eur J Neurosci. 2007 Mar;25(6):1619-30. Epub 2007 Apr 4.
Endocannabinoids (eCBs) inhibit neurotransmitter release throughout the central nervous system. Using the Ceratomandibularis muscle from the lizard Anolis carolinensis we asked whether eCBs play a similar role at the vertebrate neuromuscular junction. We report here that the CB(1) cannabinoid receptor is concentrated on motor terminals and that eCBs mediate the inhibition of neurotransmitter release induced by the activation of M(3) muscarinic acetylcholine (ACh) receptors. N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide, a CB(1) antagonist, prevents muscarine from inhibiting release and arachidonylcyclopropylamide (ACPA), a CB(1) receptor agonist, mimics M(3) activation and occludes the effect of muscarine. As for its mechanism of action, ACPA reduces the action-potential-evoked calcium transient in the nerve terminal and this decrease is more than sufficient to account for the observed inhibition of neurotransmitter release.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Cannabinoid Receptor Products

CAS 851320-29-1 O-2050

(CAS: 851320-29-1)

O-2050 is a high affinity neutral cannabinoid 1-receptor silent antagonist. It is used for the mechanistic effects and analysis of cannabinoids in the body. It ...

LEI 101 hydrochloride

LEI 101 hydrochloride is a CB2 partial agonist with pEC50 value of 8.0. It shows antinociceptive activity in a rat neuropathic pain model. LEI 101 hydrochloride...

CAS 23470-00-0 2-Palmitoylglycerol

(CAS: 23470-00-0)

2-Palmitoylglycerol is an endogenous fatty acid glycerol ester that enhances activity of 2-arachidonylglycerol. It is an endogenous agonist of the CB1 and CB2 c...

CAS 259869-55-1 JWH 133

JWH 133
(CAS: 259869-55-1)

JWH 133 is a synthetic cannabinoid and acts as a potent CB2 selective agonist with Ki value of 3.4 nM. It is used to synthesize CB2-selective cannabinoid recept...

CAS 656804-72-7 TC-C 14G

TC-C 14G
(CAS: 656804-72-7)

TC-C 14G is a potent and high affinity cannabinoid-1 (CB1) receptor inverse agonist (EC50 = 11 nM in cAMP assay; Ki = 4 nM).

CAS 183232-66-8 AM251

(CAS: 183232-66-8)

AM251 block the inhibitory effects of endocannabinoids and synthetic cannabinoid agonists on transmitter release through an action at presynaptic cannabinoid 1 ...

CAS 2854-32-2 BML-190

(CAS: 2854-32-2)

BML-190 is a selective cannabinoid CB2 receptor inverse agonist with Ki of 435 nM, with 50-fold selectivity over CB1 receptor.

CAS 464213-10-3 Ibipinabant

(CAS: 464213-10-3)

Ibipinabant is a potent and selective CB1 receptor antagonist with Ki values of 7.8 and 7,943 nM for CB1 and peripheral cannabinoid (CB2), respectively.

Chemical Structure

CAS 313998-81-1 VDM 11

Quick Inquiry

Verification code

Featured Items